Gastric intestinal type adenocarcinoma

Summary

Gastric intestinal type adenocarcinoma (MONDO:0005037) is a disease with 13 GWAS associations across 3 studies and 14 clinical trials. Top therapeutic interventions include lapatinib, bortezomib, and alvocidib. A subtype of gastric adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• GWAS associations: 13
• Clinical trials: 14

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	gastric intestinal type adenocarcinoma
Mondo ID	MONDO:0005037
EFO	EFO:0000504
NCIT	C9157
UMLS	C0279633
MedGen	79017
GARD	0027714
Anatomy (UBERON)	UBERON:0000945
Is cancer (heuristic)	no

Also known as: gastric intestinal type adenocarcinoma · gastric intestinal-type adenocarcinoma · intestinal adenocarcinoma of stomach · intestinal adenocarcinoma of the stomach · intestinal gastric adenocarcinoma · intestinal stomach adenocarcinoma · intestinal type stomach adenocarcinoma

Data availability: 13 GWAS associations (3 studies).

Disease family

This is a subtype of gastric adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › digestive system cancer › gastric cancer › gastric carcinoma › gastric adenocarcinoma › gastric intestinal type adenocarcinoma

Related subtypes (8): microinvasive gastric cancer, gastric cardia adenocarcinoma, diffuse gastric adenocarcinoma, gastric tubular adenocarcinoma, gastric papillary adenocarcinoma, mucinous gastric adenocarcinoma, signet ring cell gastric adenocarcinoma, CTNNA1-related diffuse gastric and lobular breast cancer syndrome

Genetics & variants

GWAS landscape

13 GWAS associations across 3 studies. Top hits map to 7 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs552221	3e-06	NTM	C	2.82
rs2824449	3e-06	BTG3-AS1 - C21orf91-OT1	A	1.81
rs7966502	3e-06	LINC02400 - GXYLT1	T	2.41
rs6471966	3e-06	ASPH	T	4.27
rs12967711	3e-06	SMAD7	G	66.4
rs7315261	6e-06	LINC02400 - GXYLT1	G	2.31
rs2306125	8e-06	ADAM15	T	3.14
rs7918217	8e-06	FAM171A1	C	8.66
rs11264306	9e-06	EFNA4-EFNA3	C	2.83
rs9842451	9e-06	ITPR1	G	1.77

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90432160	Shin CM	2022	0	0	rs2671655 single nucleotide polymorphism modulates the risk for gastric cancer in Helicobacter pylori-infected individuals: a genome-wide association study in the Korean population.
GCST90432161	Shin CM	2022	0	0	rs2671655 single nucleotide polymorphism modulates the risk for gastric cancer in Helicobacter pylori-infected individuals: a genome-wide association study in the Korean population.
GCST90432162	Shin CM	2022	0	0	rs2671655 single nucleotide polymorphism modulates the risk for gastric cancer in Helicobacter pylori-infected individuals: a genome-wide association study in the Korean population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	10

MAF distribution

Bucket	Variants
common (>=0.05)	10
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	10

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs552221	11	131914178	C>A,T	0.05	intron_variant	NTM	3e-06	Tier 4: intronic/intergenic
rs2824449	21	17695886	T>A,G	0.05	intron_variant	BTG3-AS1 - C21orf91-OT1	3e-06	Tier 4: intronic/intergenic
rs7966502	12	41898312	G>A,T	0.05	intron_variant	LINC02400 - GXYLT1	3e-06	Tier 4: intronic/intergenic
rs6471966	8	61647688	A>T	0.05	intron_variant	ASPH	3e-06	Tier 4: intronic/intergenic
rs12967711	18	48935813	A>G,T	0.05	intron_variant	SMAD7	3e-06	Tier 4: intronic/intergenic
rs7315261	12	41922693	A>G	0.05	intron_variant	LINC02400 - GXYLT1	6e-06	Tier 4: intronic/intergenic
rs2306125	1	155052885	T>A,C,G	0.05	intron_variant	ADAM15	8e-06	Tier 4: intronic/intergenic
rs7918217	10	15294897	T>A,C	0.05	intron_variant	FAM171A1	8e-06	Tier 4: intronic/intergenic
rs11264306	1	155070849	C>A,G,T	0.05	intron_variant	EFNA4-EFNA3	9e-06	Tier 4: intronic/intergenic
rs9842451	3	4617183	G>A	0.05	intron_variant	ITPR1	9e-06	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 14.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	8
PHASE1/PHASE2	3
PHASE1	2
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00061932	PHASE2	COMPLETED	Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach
NCT00064259	PHASE1/PHASE2	TERMINATED	A Phase I/II Study of Oblimersen Plus Cisplatin and Fluorouracil in Gastric & Esophageal Junction Cancer
NCT00084604	PHASE2	COMPLETED	Irinotecan, Cisplatin, and Bevacizumab in Treating Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT00084617	PHASE2	COMPLETED	Phase II Study of Oxaliplatin, Irinotecan, and Capecitabine in Advanced Gastric/Gastroesophageal Junction Carcinoma
NCT00103324	PHASE2	COMPLETED	S0413 Lapatinib in Treating Patients With Locally Advanced or Metastatic Stomach Cancer
NCT00991952	PHASE2	COMPLETED	Irinotecan Hydrochloride With or Without Alvocidib in Treating Patients With Advanced Stomach or Gastroesophageal Junction Cancer That Cannot Be Removed By Surgery
NCT01212822	PHASE2	COMPLETED	Bevacizumab and Combination Chemotherapy Before Surgery in Treating Patients With Locally Advanced Esophageal or Stomach Cancer
NCT01231399	PHASE1/PHASE2	COMPLETED	Everolimus and Combination Chemotherapy in Treating Patients With Metastatic Stomach or Esophageal Cancer
NCT01260701	PHASE2	COMPLETED	Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
NCT01612546	PHASE2	COMPLETED	Pilot Trial of CRLX101 in Treatment of Patients With Advanced or Metastatic Stomach, Gastroesophageal, or Esophageal Cancer That Cannot be Removed by Surgery
NCT02344810	PHASE1/PHASE2	WITHDRAWN	C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer
NCT00028496	PHASE1	COMPLETED	Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
NCT01643499	PHASE1	COMPLETED	Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
NCT01939275	Not specified	COMPLETED	64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
LAPATINIB	4	3
BORTEZOMIB	4	1
ALVOCIDIB	3	3
OBLIMERSEN SODIUM	3	1